Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3q26q28 Deletion Syndrome C6010434
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3q26q28 Deletion Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3q26q28 Deletion Syndrome C6010434
A genetic condition involving deletion of part of chromosome 3q26q28, typically causing developmental delays, growth issues, and multiple congenital differences.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3q26q28 Deletion Syndrome C6010434
Variable
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3q26q28 Deletion Syndrome C6010434
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3q26q28 Deletion Syndrome C6010434
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3q26q28 Deletion Syndrome C6010434
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q26q28 Deletion Syndrome C6010434
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3q26q28 Deletion Syndrome C6010434
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3q26q28-deletion-syndrome-C6010434 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q26q28 Deletion Syndrome C6010434 | Discriminating power |
|---|---|---|---|
| Developmental delay | Described as a primary neurologic feature, often beginning in early childhood. | Also described, with variable onset and possible growth or congenital differences. | Low |
| Seizures | Reported as a characteristic neurologic feature; severity is not uniform. | Not established by the supplied description and should not be assumed. | Moderate |
| Congenital differences | Not the defining feature in the supplied source; movement difficulty may occur. | Multiple congenital differences and growth issues are described. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early neurologic presentation
Consider when developmental delay, seizures, or movement difficulty suggest a serine-related metabolic disorder.
Moderate
Metabolic evaluation
Appropriate when amino-acid or serine abnormalities are being investigated; exact cutoffs are not supplied.
Moderate
Targeted gene suspicion
Consider when clinical findings support a disorder of serine biosynthesis rather than a chromosomal syndrome.
Low
Choose 3q26q28 Deletion Syndrome C6010434 when
Multiple congenital findings
Consider when developmental delay occurs with growth issues or several congenital differences.
Moderate
Variable onset
The supplied onset is variable, so timing alone does not exclude the syndrome.
Low
Chromosomal suspicion
Consider when the pattern suggests a deletion rather than a primary metabolic enzyme deficiency.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3q26q28 Deletion Syndrome C6010434 | Interpretation |
|---|---|---|---|
| Amino-acid or serine studies | May support impaired serine production; no cutoff is established here. | No characteristic amino-acid result is supplied. | An abnormal result is not itself a diagnosis and needs clinician review. |
| Disease-specific genetic testing | May assess the relevant serine-biosynthesis gene when clinically indicated. | Not the primary test for a chromosomal deletion. | Gene testing and chromosomal testing answer different questions. |
| Chromosomal microarray or karyotype | Not expected to define this metabolic disorder. | May identify a 3q26q28 deletion when clinically indicated. | A deletion finding requires laboratory and clinical correlation. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- A severe chronic course is suggested, but individual outcome is not established.
- Factors
- Neurologic features and response to clinician-directed care may influence course.
3q26q28 Deletion Syndrome C6010434
- Outcome
- A moderate chronic course is suggested, with substantial individual variation.
- Factors
- Extent of developmental, growth, and congenital findings may matter.
Time frame: Long-term; exact timelines are not supplied.
Prognosis should be based on confirmed diagnosis, complications, and clinical follow-up.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Seizures, developmental delay, and movement difficulty are described. Developmental delay is described; seizures are not established here. Neurologic burden may differ and requires individual assessment. |
| Growth and congenital issues | Not established as defining complications in the supplied source. Growth issues and multiple congenital differences are described. The range and severity are not quantified here. |
| Treatment-related burden | Serine supplementation and anticonvulsants may be used as needed. No specific treatment is supplied; care is likely supportive and individualized. Doses and outcomes should not be inferred from this comparison. |
Patient education highlights
- HighDifferent causes
One condition involves serine metabolism; the other involves missing chromosomal material. Neither is described as communicable.
- HighTesting limits
Abnormal laboratory or genetic findings need confirmation and do not replace a clinician’s diagnosis.
- MediumCare planning
Both are chronic in the supplied data, so developmental, neurologic, and supportive needs should be reviewed individually.